| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/26/2011 | EP2277887A2 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 01/26/2011 | EP2277880A1 Macrolides with VEGF transcription suppression activity |
| 01/26/2011 | EP2277879A1 Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| 01/26/2011 | EP2277878A1 Process for production of ethynylthymidine compound using 5-methyluridine as starting raw material |
| 01/26/2011 | EP2277877A1 Quinazoline derivatives as kinase inhibitors |
| 01/26/2011 | EP2277876A1 Substituted pyrimidines for the treatment of cancer |
| 01/26/2011 | EP2277850A1 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| 01/26/2011 | EP2277526A1 Pharmaceutical composition with tetrahydroisohumulone |
| 01/26/2011 | EP2277521A1 Tamper-resitant oral opioid agonist formulations |
| 01/26/2011 | EP2277519A2 Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure |
| 01/26/2011 | EP2276494A1 Stable aqueous compositions comprising bioactive creatine species |
| 01/26/2011 | EP2276478A1 Methods of administering prostratin and structural analogs thereof |
| 01/26/2011 | EP2276463A2 Diterpene glycosides as natural solubilizers |
| 01/26/2011 | EP2276342A1 Substituted tetracycline compounds |
| 01/26/2011 | EP1496892B1 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| 01/26/2011 | EP1480941B1 Urea derivatives as hiv aspartyl protease inhibitors |
| 01/26/2011 | EP1446382B1 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
| 01/26/2011 | EP1404365B1 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 01/26/2011 | EP1365769B1 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| 01/26/2011 | EP1143925B2 Topical composition comprising n-acetylglucosamine |
| 01/26/2011 | CN201720025U Mixing equipment for preparation process of cooling oil plant medicine combination |
| 01/26/2011 | CN1918128B Fused ring 4-oxopyrimidine derivative |
| 01/26/2011 | CN1796388B Sesamin/episesamin compositions |
| 01/26/2011 | CN101959899A New compound derived from germinated brown rice, and agent containing said compound as an active ingredient for prevention or amelioration of neuropathy |
| 01/26/2011 | CN101959868A Fibrosis inhibitor |
| 01/26/2011 | CN101959542A Drug delivery system |
| 01/26/2011 | CN101959532A Pharmaceutical composition for transnasal administration |
| 01/26/2011 | CN101959530A Prophylactic or therapeutic agent for diabetes or obesity |
| 01/26/2011 | CN101955917A Virus-like particle containing porcine parvovirus VP2 and somatostatin chimeric protein |
| 01/26/2011 | CN101955502A thiogalactosiTtderivatives, preparation method and application thereof |
| 01/26/2011 | CN101955477A 2-cyclopropyl-4-substituted thiophenyl quinoline compounds as well as intermediate, preparation method and application thereof |
| 01/26/2011 | CN101954083A Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate |
| 01/26/2011 | CN101954081A Using method for improving medicament effect of pollen pini |
| 01/26/2011 | CN101954007A Couchgrass root product and preparation method thereof |
| 01/26/2011 | CN101953819A Improved transdermal delivery system for administration of rotigotine |
| 01/26/2011 | CN101953800A Technology for producing water-soluble coenzyme Q10 and mannitol composite powder |
| 01/26/2011 | CN101396447B Method for increasing the predation performance of spider using agrimony extract |
| 01/26/2011 | CN101396446B Method for increasing the parasitism performance of parasitic wasp |
| 01/26/2011 | CN101167974B Quality control method of 'xuhanting' preparation |
| 01/26/2011 | CN101077875B Boronic ester and acid compounds, synthesis and uses |
| 01/25/2011 | US7875727 Benzimidazole vascular damaging agents |
| 01/25/2011 | US7875712 inhibitors of apoptosis and IL-1 beta secretion; mediate cell apoptosis and inflammation; good cell penetration and pharmacokinetic properties; [3S/R(2S)]3-[2-(Carbazol-9-yl-2-oxo-ethyl)-pentanoylamino]-5-fluoro-4-oxo-pentanoic acid |
| 01/25/2011 | US7875709 Nucleic acids encoding interleukin-18 mutants |
| 01/25/2011 | US7875677 Micellar drug delivery systems for hydrophobic drugs |
| 01/25/2011 | US7875637 Benzimidazole derivative and use as a II receptor antagonist |
| 01/25/2011 | US7875301 comprising Cucurbita moschata, Carthamus tinctorius, Plantago asiatica and Lonicera japonica; treating neutropenia and aplastic anemia |
| 01/25/2011 | US7875290 Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form |
| 01/25/2011 | CA2635963C Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 01/25/2011 | CA2599158C Pharmaceutical agent comprising solifenacin |
| 01/25/2011 | CA2480367C 4-(diarylmethyl)-1-piperazinyl derivatives |
| 01/25/2011 | CA2477714C New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament |
| 01/25/2011 | CA2476983C Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma |
| 01/25/2011 | CA2472776C Process for the manufacture of hmg-coa reductase inhibitors |
| 01/25/2011 | CA2469594C Crystal of bicalutamide and production method thereof |
| 01/25/2011 | CA2468681C Adenosine a2a receptor antagonists |
| 01/25/2011 | CA2468673C Compounds specific to adenosine a1 and a3 receptors and uses thereof |
| 01/25/2011 | CA2463146C Crystalline sodium salt of telmisartan and the use of same as an angiotensin antagonist |
| 01/25/2011 | CA2454532C Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities |
| 01/25/2011 | CA2447765C 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 01/25/2011 | CA2443868C 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| 01/25/2011 | CA2432582C Sulfamidothienopyrimidines |
| 01/25/2011 | CA2410000C Compositions and methods comprising plasmid dna for wound healing and for repairing and regenerating tissue |
| 01/25/2011 | CA2404125C Sulphonamido-substituted bridged bicycloalkyl derivatives |
| 01/25/2011 | CA2391650C Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
| 01/25/2011 | CA2388468C Mediators of hedgehog signalling pathways, compositions and uses related thereto |
| 01/25/2011 | CA2385322C A substantially cell membrane impermeable compound and use thereof |
| 01/25/2011 | CA2381882C Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/25/2011 | CA2339834C Water soluble prodrugs of hindered alcohols or phenols |
| 01/25/2011 | CA2303509C Modified timp |
| 01/25/2011 | CA2295540C Improved anti-ige antibodies and method of improving polypeptides |
| 01/25/2011 | CA2175429C Pharmaceutical compositions and methods |
| 01/20/2011 | WO2011009042A2 Antigen compositions and methods of inhibiting campylobacter jejuni bacterial infection and uses of the antigen compositions |
| 01/20/2011 | WO2011007899A1 Glycine transporter inhibitors |
| 01/20/2011 | WO2011007882A1 Insulin-producing cell inducer, glucose intake enhancer, and therapeutic agent for diabetes or diabetes complications |
| 01/20/2011 | WO2011007866A1 Agent for treatment of myotonic dystrophy |
| 01/20/2011 | WO2011007864A1 Inhibitor of blood gip level elevation |
| 01/20/2011 | WO2011007859A1 Dna fragment and pharmaceutical composition |
| 01/20/2011 | WO2011007856A1 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer |
| 01/20/2011 | WO2011007853A1 Monoclonal antibody for cancer-specific isoform |
| 01/20/2011 | WO2011007819A1 Pharmaceutical product containing lactam or benzene sulfonamide compound |
| 01/20/2011 | WO2011007794A1 Zeolite and sericite-containing composition for medical or medical assisting uses |
| 01/20/2011 | WO2011007756A1 Heterocyclic compound and use thereof |
| 01/20/2011 | WO2011007747A1 Sugar chain-added ailim extracellular domain and method for producing same |
| 01/20/2011 | WO2011007722A1 3-substituted-2-furancarboxylic acid hydrazide derivative and pharmaceutically acceptable salt thereof |
| 01/20/2011 | WO2011007633A1 Crystals of pyrroloquinolinequinone sodium salts |
| 01/20/2011 | WO2011007612A1 Anti-inflammatory agent for oral application, and anti-inflammatory peptide for oral application |
| 01/20/2011 | WO2011007552A1 Bad breath-removing agent |
| 01/20/2011 | WO2011007320A1 Humic substances and therapeutic uses thereof |
| 01/20/2011 | WO2010120370A3 Gamma-amino-butyric acid derivatives as gabab receptor ligands |
| 01/20/2011 | US20110015724 Medical device having hydrophilic coatings |
| 01/20/2011 | US20110015437 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/20/2011 | US20110015195 Aryl ureas with angiogenisis inhibiting activity |
| 01/20/2011 | US20110015188 Treatment of Seasonal Conditions |
| 01/20/2011 | US20110015165 Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| 01/20/2011 | US20110014301 Metal compounds, mixed or sulphated, as phosphate binders |
| 01/20/2011 | US20110014293 Cleavage kit, and gene therapy by using the same and nucleic acid cleavage detection apparatus |
| 01/20/2011 | US20110014289 Reticulated Elastomeric Matrices, Their Manufacture and Use in Implantable Devices |
| 01/20/2011 | US20110014282 Pharmaceutical composition for poorly soluble drugs |
| 01/20/2011 | US20110014277 Smoking Cessation With Body Weight Maintenance And Nutritional Supplement |
| 01/20/2011 | US20110014267 Biosynthetic cartilaginous matrix and methods for their production |